Latest news with #OA
Yahoo
3 hours ago
- Health
- Yahoo
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 ( that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: 'The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.' The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain. Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo's FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks. Professor O'Sullivan stated, 'ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.' Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain. OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, efficacy of the Company's product candidates, results and conclusions from preclinical studies and clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
PA making state government workforce stronger and more competitive
May 26—WILKES-BARRE — To mark the one year anniversary of Gov, Josh Shapiro's executive order to strengthen the Commonwealth state employee workforce, the Shapiro Administration this week announced the completion of key milestones to improve recruitment, hiring, retention, and development so that Commonwealth agencies can continue to attract highly qualified and dedicated public servants to address the needs of Pennsylvanians. Initiatives to hire more bilingual workers, expand access to childcare, and engage with job seekers are delivering real results that build on Gov. Shapiro's goal of making the Commonwealth a top employer. "Pennsylvania state government should be a place where the best and brightest want to work; a place where every Pennsylvanian, no matter their background, can see themselves thriving in meaningful careers," said Secretary of Administration Neil Weaver. "Through the work of the HIRE Committee and the actions taken through the Governor's executive order, we are making tangible progress in creating a workforce that is as diverse, dynamic, and innovative as the people we serve." "At DGS, we're proud to play a key role in supporting Governor Shapiro's vision of making the Commonwealth a top-tier employer by investing in the people who serve Pennsylvania every day," said Secretary of General Services Reggie McNeil. "From expanding access to quality childcare to improving physical accessibility and ensuring dignity through free menstrual products and single-use restrooms, our work is focused on creating a workplace that values every employee and meets the needs of a modern workforce." Over the past year, the HIRE Committee has built on this foundation through targeted initiatives and pilot programs that include: —Eliminating Waiting Periods for Benefits — Effective Aug. 1, 2025, the waiting period for new hires to enroll dependents into PEBTF medical, prescription drug, dental, and vision coverage without paying additional out of pocket costs will be eliminated. —Offering Financial Incentives for Bilingual Employees — Launched in April, this pilot program at L&I provides a $1.00 per hour bonus — almost $1,000 more over the course of the 6-month pilot — for bilingual employees in certain Unemployment Compensation and PA CareerLink positions to ensure Pennsylvanians who speak a language other than English receive efficient, effective service. —Fostering Re-entrant Success through Employment Opportunities — OA is piloting a hiring program with the Department of Corrections to promote pathways to employment in state government for people who have previously interacted with the criminal justice system. —Hosting the Second Annual Commonwealth Job Fair — OA hosted the second multi-agency job fair for job seekers in the Harrisburg area in March, attracting over 1,000 registrants to learn about open positions and opportunities to join public service. —Enhancing Services for Pennsylvanians with Limited English Proficiency — After hiring the first enterprise language access program manager, OA has prioritized expanding technical assistance and training for agency staff on procuring high-quality translations and language services, supporting agencies as they develop language access plans, and building open and continuous communication with agencies to distribute translated materials and information to Pennsylvanians who need it most. —Promoting Employee Work/Life Balance — The Commonwealth has expanded assistance for mental health and substance misuse issues, family care-giving, and more to support the well-being of all employees. —Expanding Access to Employee Child Care — DGS is managing the expansion of the Keystone Early Learning Center, a year-round childcare facility available to Commonwealth employees. —Improving Accessibility of Commonwealth Buildings — DGS continues to lead an accessibility study that is the first step in helping to improve access and inclusivity for individuals with disabilities throughout the Pennsylvania Capitol Complex. —Offering Free Menstrual Products — DGS has placed menstrual products in woman's restrooms and single-use restrooms throughout Commonwealth buildings directly managed by the agency to ensure that essential hygiene products are readily available to employees and visitors who need them. —Continuing to Add Single-Use Restrooms — DGS has added 12 single-use restrooms in state government facilities following the issuance of the HIRE executive order. State graduates inaugural class of 15 small business owners from Mentor Protégé Program The Pennsylvania Department of General Services (DGS) this week graduated the inaugural cohort of the Mentor Protégé Program (MPP) — a key initiative started under the Shapiro-Davis Administration to expand opportunities and access for small, small diverse, and veteran-owned businesses seeking to compete in the Commonwealth's procurement process. The MPP, established under Governor Shapiro's Executive Order 2023-18, provides small business owners with one-on-one mentoring relationships with seasoned prime contractors. Mentors provide guidance, support, and valuable insights to help protégés improve their business management and contract bidding skills which could be useful in acquiring additional Commonwealth business. "This program is a reflection of the Shapiro-Davis Administration's commitment to economic equity and opportunity," said DGS Secretary Reggie McNeil. "By investing in mentorship and creating space for small, small diverse and veteran-owned businesses to grow, we're strengthening Pennsylvania's economy and seeking to ensure that our procurement processes reflect the diversity and talent of our business community." This first cohort, focused on IT services, included 15 business participants who engaged in targeted programming on business development, procurement readiness, leadership, and strategic planning. Lieutenant Governor Austin Davis participated in the ceremony with a special pre-recorded message, applauding the graduates and reaffirming the Shapiro-Davis Administration's commitment to breaking down barriers for small, small diverse, and veteran-owned businesses. "Small businesses are the backbone of our communities—and when we empower them, we uplift all of Pennsylvania," Davis said. "This administration is committed to cutting red tape, reducing wait times, and creating real ladders of opportunity." League of Women Voters of Wilkes-Barre to hold Annual Meeting June 5 The League of Women Voters of Wilkes-Barre will hold its annual dinner meeting on Thursday, June 5, at 6 p.m., at Theo's Metro Restaurant, 596 Mercer Ave., Kingston. The guest speaker will be Ned Miller, the Northeast Regional Representative for Fair Districts PA. Fair Districts PA is a nonpartisan, statewide coalition that advocates redistricting reform to ensure that the process of determining Pennsylvania's congressional and state legislative districts is fair and transparent. The cost of the buffet dinner is $42 for members and $45 for non-members. RSVP by Friday, May 30. Founded in 1944, The League of Women Voters of the Wilkes-Barre Area (LWVWBA) is a nonpartisan organization that presents citizens of the Wilkes-Barre area with educational tools about issues and candidates so they can make informed decisions on election day. Activities include publishing a government directory and voters guides, voter registration drives, and hosting events where constituents can meet their elected officials. Entirely run by local volunteers, League membership is open to all, regardless of political affiliation or gender. To reserve your seat at the Annual Meeting, contact the League at — 570-675-3429 — or email at lwvwba@ Or visit the League Website at — League updates can be found on Facebook @LWVWB. Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
Sydney Morning Herald
16-05-2025
- Entertainment
- Sydney Morning Herald
‘Picture of misery': Opera Australia posts $10 million loss as audiences hit a cliff
Opera Australia has plunged deeper into financial crisis, posting a $10 million operating deficit as chair Rod Sims defended its worst results since the pandemic. Australia's largest performing arts company was forced to draw down on its emergency capital fund to offset its losses after its Sydney winter season and its much-hyped run of Sunset Boulevard failed to meet box office forecasts. Melbourne performances of the Andrew Lloyd Webber musical last year were blighted by poor reviews, unsold seats and long absences by its lead, Sarah Brightman, due to injury. In addition, OA blamed the closure of the company's State Theatre home in Melbourne and the need to perform in other venues for the hit to its bottom line. The results, branded a disaster privately by some long-term supporters who have been agitating for board changes, ratchet pressure on the board headed by Sims to reverse its fortunes as it approaches its 70th anniversary year in 2026. Loading They land as OA has yet to fill the key roles of artistic director Jo Davies and chief executive Fiona Allen, who resigned in quick succession of each other. The board is also digesting the findings of an independent review critical of OA's culture, morale and workplace structure which has been undertaken by veteran corporate adviser, Gabrielle Trainor. OA's box office revenue sank to $50.7 million in 2024, down from $65.7 million the previous year, according to its annual report.
The Age
16-05-2025
- Entertainment
- The Age
‘Picture of misery': Opera Australia posts $10 million loss as audiences hit a cliff
Opera Australia has plunged deeper into financial crisis, posting a $10 million operating deficit as chair Rod Sims defended its worst results since the pandemic. Australia's largest performing arts company was forced to draw down on its emergency capital fund to offset its losses after its Sydney winter season and its much-hyped run of Sunset Boulevard failed to meet box office forecasts. Melbourne performances of the Andrew Lloyd Webber musical last year were blighted by poor reviews, unsold seats and long absences by its lead, Sarah Brightman, due to injury. In addition, OA blamed the closure of the company's State Theatre home in Melbourne and the need to perform in other venues for the hit to its bottom line. The results, branded a disaster privately by some long-term supporters who have been agitating for board changes, ratchet pressure on the board headed by Sims to reverse its fortunes as it approaches its 70th anniversary year in 2026. Loading They land as OA has yet to fill the key roles of artistic director Jo Davies and chief executive Fiona Allen, who resigned in quick succession of each other. The board is also digesting the findings of an independent review critical of OA's culture, morale and workplace structure which has been undertaken by veteran corporate adviser, Gabrielle Trainor. OA's box office revenue sank to $50.7 million in 2024, down from $65.7 million the previous year, according to its annual report.
Business Wire
12-05-2025
- Business
- Business Wire
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation ('Genascence'), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). Results from the 12-month analysis showed the study met the primary endpoint, demonstrating continued safety and tolerability across all doses tested, as well as the key secondary endpoint showing sustained IL-1Ra expression in synovial fluid, building on data reported through the six-month visit. GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that blocks IL-1 signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single intra-articular injection into the affected joint. The U.S. Food and Drug Administration (FDA) granted GNSC-001 Fast Track designation in the fourth quarter of 2024. Genascence recently completed a successful meeting with the FDA on the design of the Phase 2b/3 clinical trial of GNSC-001 focused on clinical efficacy and plans to initiate the Phase 2b/3 study in 2026. 'Osteoarthritis is incapacitating, causing years of pain and disability for people living with the disease. Current treatment options are limited to managing pain and do not treat the underlying disease itself,' said Thomas Chalberg, Ph.D., founder and CEO of Genascence. 'The 12-month safety and sustained IL-1Ra expression data affirms the promise of GNSC-001 to potentially transform the treatment paradigm for OA. We are pleased by the successful meeting with the FDA, and look forward to initiating the study, transitioning GNSC-001 to late-stage clinical development so we can bring a new treatment option to people suffering from this disabling disease.' 'GNSC-001 is the first IL-1 inhibitor that has been shown to generate IL-1Ra expression levels that reach and maintain therapeutic thresholds long-term following a single administration,' said Annahita Keravala, Ph.D., chief scientific officer (CSO) of Genascence. 'Results from the DONATELLO clinical trial suggest that our novel therapeutic approach, a local gene therapy can potentially have therapeutic benefit in knee OA, a disease for which there are no treatments beyond management of symptoms. This would be transformative for people suffering from this debilitating condition, and thus warrants further development.' "These results from the DONATELLO trial reflect the kind of innovation CIRM was created to support,' said Lisa Kadyk, Ph.D., CIRM Fellow, Clinical Development at the California Institute for Regenerative Medicine (CIRM), which supported the DONATELLO clinical trial with a $12 million award. 'By harnessing the power of gene therapy, GNSC-001 represents a novel and potentially disease-modifying approach to treating osteoarthritis. We are encouraged by the 12-month safety and biomarker data and proud to have supported this important step toward a more effective, long-term treatment for people living with knee OA." Dr. Keravala will present data from the six-month interim analysis of the DONATELLO clinical trial at the 28 th Annual American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, being held May 13-17, 2025 in New Orleans, LA and virtually. The poster presentation details are provided below. Title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 1b Study Evaluating Safety, Tolerability, and Pharmacodynamics of a Local AAV-Mediated Anti-Interluekin-1 Gene Therapy in Subjects with Knee Osteoarthritis: 6-Month Interim Results Date/Time: Thursday, May 15, 2025, 5:30-7:00 pm CT Location: Poster Hall Abstract Number: AMA616 Poster Number: 1849 Abstracts can be found at About the DONATELLO Clinical Trial The DONATELLO Phase 1b clinical trial (NCT05835895) is a double-blind, placebo-controlled dose-ranging study designed to evaluate the safety, tolerability, and pharmacodynamics of a single intra-articular injection of GNSC-001 in patients with OA of the knee. The study enrolled 67 participants with OA at 10 centers across the U.S. The first five groups were randomized to receive GNSC-001 at doses of 110 12 vg or 110 13 vg, with or without a short course of oral steroids for immune-conditioning, or a placebo (saline) injection. The trial was expanded to enroll an additional, non-randomized arm. In this arm, pre-treatment synovial fluid sampling was required for entry, and subjects received 110 13 vg GNSC-001 with an abbreviated three-day course of oral steroids plus a local, intra-articular steroid injection. Data and Safety Summary The primary endpoints of the DONATELLO clinical trial are safety and tolerability. Through 12 months of follow-up, data show that GNSC-001 was well tolerated, with no treatment-emergent or treatment-related deaths, serious adverse events (SAEs), or adverse event (AE)-related withdrawals reported. The most common target knee AEs included arthralgia, joint swelling, and joint effusion. The study's secondary endpoints include expression levels of interleukin-1 receptor antagonist (IL-1Ra) in synovial fluid at Month 12, as well as change from baseline to Month 12. Results revealed that mean expression of IL-1Ra reached target therapeutic levels in multiple arms of the study and remained above the target threshold throughout the 12-month follow up period. Immune-conditioning with a short course of steroids generally supported higher levels of prolonged IL-1Ra expression. The DONATELLO clinical trial was supported by a $12 million award from the California Institute for Regenerative Medicine (CLIN2-14265). About Osteoarthritis (OA) of the Knee Osteoarthritis (OA) is a progressive joint disease that is a leading cause of disability. It is characterized by destruction of cartilage and structural changes in bone within the joint, which contribute to pain and loss of joint function. Osteoarthritis affects more than 30 million Americans and is increasing as a result of the aging population and increasing prevalence of obesity. Osteoarthritis represents a major economic burden, owing to direct medical costs and loss of productivity. Each year, millions of patients are treated for knee OA with NSAIDs, opioids, and steroid injections into the knee to manage their knee pain. There are no currently available therapies known to alter or slow down OA progression. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit
